explore -WSS

explore

author：explore 2025-10-01 21:36:23 - browse：39882

Boxes of Ozempic photo illustration. -- health coverage from STAT — Mario Tama/Getty Images

LONDON — Novo Nordisk’s diabetes medication Ozempic cut the risk of patients developing advanced kidney disease or dying from kidney or heart complications, the company said Tuesday, adding to the evidence the wildly popular drug has broader health benefits for patients beyond addressing their diabetes.

Overall, Ozempic lowered the risk of progression of patients’ kidney disease and of related health events by 24% versus placebo, according to the topline results. The company, which will present full data from the study later this year, said it would file for an expanded approval of Ozempic based on the data in both the U.S. and Europe.

The positive announcement had been expected since October, when Novo announced it was ending the FLOW trial early because an interim data analysis showed the drug was surpassing the study’s goals. Still, the results provide an important data point for Novo both as its medicines face increasing competition and as it tries to get more insurers to cover its related obesity drug Wegovy.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Lasker Awards 2023: Winners in biomedical research

WSS

Why did Pfizer dish out millions for a Super Bowl ad?

Key House Republican on health care plans exit from Congress

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Medicare Advantage proposed rates disappoint insurers

Why are Kaiser Permanente staff considering a strike?

knowledge

explore

hotspot

The cancer drug shortage isn’t new — and neither are the solutions

BioAge raises $170M for combination therapy with Zepbound

Alkermes shareholders re

Biden report: The neurospychology of memory and aging

Medical records are filled with copy

Experts study whether long Covid risk adds up with each reinfection

Apple is now the first public company to be valued at $3 trillion

How Vertex's cystic fibrosis drug is changing patients' lives

After affirmative action ruling, medical educators look to 'holistic review'

Doctors' information doesn't help them choose wisely when sick

focus

Ukraine and a new approach to mental health in war

What we’ve learned from the Aduhelm mess

Gilead might be held responsible for not developing a drug

Intarcia’s device

Why are Kaiser Permanente staff considering a strike?

Hearing on Medicare drug price negotiation gets unusually heated

hotspot

knowledge

explore

hotspot